ASLAN Pharmaceuticals Limited ASLN
Day range unavailable
52-week range unavailable
- Market cap
- 1.70M
- Revenue (ttm)
- 12.00M
- Profit margin
- -291.89%
- Shares out
- 2.83M
- Forward P/E
- -0.03
- Beta
- 1.40
- Analysts
- Buy
- Price target
- 72.00 (+11900.0%)
- Earnings date
- Aug 9, 2024
Key statistics
- Enterprise value
- 288.33M
- PEG ratio
- 0.00
- Price / sales
- 0.14
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 18.40M
- Total debt
- 26.67M
- Return on equity
- 0.00%
- Short % of float
- 1.46%
- 50-day average
- 1.07
- 200-day average
- 3.48
Analyst view
Consensus: buy
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -3.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -5.44 | — | — | — |
| Apr 12, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 27, 2023 | Sep 1, 2023 | -6.80 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -6.96 | — | — | — |
| Apr 28, 2023 | Mar 1, 2023 | -6.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2023 | Roth MKM | reit | Buy | Buy |
| Jul 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 22, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2023 | Roth MKM | init | — | Buy |
About ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- Website
- aslanpharma.com
News
Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ) 
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF) 
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates 
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation 
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal - Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Wednesday's After-Market Session 
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
Your note
Sign in to keep a note on ASLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vivo Capital, LLC | 37.39% | 2,840,908 | 10.37M | Jun 29, 2023 |
| Tang Capital Management, LLC | 14.85% | 1,128,068 | 4.12M | Jun 29, 2023 |
| BVF Inc. | 13.82% | 1,049,999 | 3.83M | Jun 29, 2023 |
| Parkman Healthcare Partners LLC | 6.67% | 506,621 | 1.85M | Jun 29, 2023 |
| Temasek Holdings (Private) Limited | 4.42% | 335,615 | 1.22M | Jun 29, 2023 |
| Sio Capital Management, LLC | 3.34% | 254,150 | 927.65K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Emerging Markets ETF | 0.13% | 9,908 | 21.05K | Aug 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 7,968 | 31.87K | May 30, 2023 |